Preparation for the global Phase 1/2 trial of NS-050/NCNP-03
First written in FY2023. 3 of 5 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「• The global Phase 1/2 trial of NS-050/NCNP-03, a treatment for Duchenne muscular dystrophy, was launched in October 2024.」
NS-050/NCNP-03 progressed from the preparation stage for the global Phase 1/2 trial to the trial launch stage in October 2024. - FY2024-Q3RestatedAnnual report
「• Preparation is underway for the global Phase 1/2 trial of NS-050/NCNP-03, a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 1/2 trial of NS-050/NCNP-03 was disclosed again. - FY2024-Q2RestatedAnnual report
「• Preparation is underway for the global Phase 1/2 trial of NS-050/NCNP-03, a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 1/2 trial of NS-050/NCNP-03 was disclosed again. - FY2024-Q1RestatedAnnual report
「• Preparation is underway for the global Phase 1/2 trial of NS-050/NCNP-03, a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 1/2 trial of NS-050/NCNP-03 was disclosed again. - FY2023First statedAnnual report
「Preparation is underway for the global Phase 1/2 trial of NS-050/NCNP-03, a treatment for Duchenne muscular dystrophy.」
The preparation status for the global Phase 1/2 trial of NS-050/NCNP-03 for Duchenne muscular dystrophy was disclosed for the first time.